Adalvo today announced the successful pan-European launch of Nintedanib Soft Gel Capsules, delivered simultaneously across its European partners.
Through operational excellence, Adalvo ensured every element -dossiers, supply chains, and commercial arrangements - was secured to be able to supply multiple partners across all European markets from day one following patent expiry.
Anil Okay, CEO at Adalvo, commented: "This launch is a strong demonstration of what Adalvo is built to do. Our ability to be present across every European market simultaneously, from the very first day of availability, reflects the preparation, coordination, and execution that our partners rely on us for. Speed is a competitive advantage in generics, and we delivered exactly that — ensuring our partners could hit the ground running and that patients could benefit from access to this important therapy as soon as possible."
Nintedanib is a well-established tyrosine kinase inhibitor with a broad therapeutic profile spanning serious respiratory and oncological conditions. This product is developed based on two distinguished reference brands, Ofev and Vargatef. Ofev is indicated for the treatment of Idiopathic Pulmonary Fibrosis (IPF), Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype (PF-ILD), and Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD), and Vargatef addresses Non-Small Cell Lung Cancer (NSCLC).
Adalvo continues to expand its European and global portfolio, with a strong pipeline of dossiers across a broad range of therapeutic areas and markets.